|Salary:||£37,474 to £42,155 per annum pro rata|
|Placed On:||18th January 2023|
|Closes:||15th February 2023|
Faculty of Life Sciences
Contract Type: Fixed Term for 27 months
Interview Date: To be confirmed
An excellent opportunity has arisen for a post-doctoral research associate, funded by Worldwide Cancer Research, to join a dynamic, multidisciplinary, successful drug discovery team focused on driving translation of a new class of tumour-selective therapeutic towards the clinic. You will play a central role in the development of a novel tumour endoprotease-targeted inhibitor of DNA repair for the treatment of neuroblastoma (BBA-Rev. Cancer, 2021, 1876, 188641; Curr. Res. Pharmacol. Drug Discov. 2021, 2, 100017). The concept for the prodrug is based on ICT2588 (Cancer Res., 2010, 70, 6902-6912; Mol. Pharm., 2014, 11, 1294-1300, Biochem. Pharmacol., 2022, 201, 115095), our novel targeted anti-vascular agent, which was previously licenced to University spin-out company Incanthera plc. (www.incanthera.com).
You will have a PhD and relevant experience in chemical biology, cell or molecular biology or a related discipline, and laboratory research experience. The role is ideal for someone who has a biology background and is keen to gain skills in peptide-based synthesis, or someone who has good experience in both disciplines. The post will largely focus on the biological evaluation of novel peptide prodrugs and combinations in vitro and ex vivo, with an element of peptide drug conjugate synthesis (for which full training will be provided). We welcome enthusiastic, motivated and driven team-players interested in preclinical cancer research, willing to work in a dynamic research environment, and keen to build upon their skills and experience.
All work will be carried out at the Institute of Cancer Therapeutics (ICT) at the University of Bradford, under the guidance of an experienced multi-disciplinary team, namely Prof Paul Loadman, Dr Steve Shnyder, Prof Sherif El-Khamisy, and Prof Robert Falconer. The ICT has an international reputation for translational research leading to the identification of novel therapies and additionally provides laboratory support to early phase clinical trials. The ICT has dedicated facilities for cell and molecular biology, cancer pharmacology, drug metabolism and pharmacokinetics, medicinal chemistry, drug analysis, and in vivo tumour biology, all under one roof. See https://www.bradford.ac.uk/ict/ for further information.
Informal enquiries prior to application may be made to Prof Robert Falconer (Principal Investigator), Institute of Cancer Therapeutics (e-mail: firstname.lastname@example.org).
A curriculum vitae and covering letter should be included with your application. Correspondence regarding your application for this role including invitations to interview will be sent via email. Please check your Spam/Junk email folder in case these messages have been delivered there instead of your inbox.
Confronting Inequality : Celebrating Diversity
At the University of Bradford we accept people for who they are regardless of age, disability, gender identity, marital status, ethnicity, faith, sexual orientation or socio-economic background and whether you’re pregnant or on maternity leave.
In line with the University’s commitment to equality charters including Athena Swan, Race Equality Charter, Disability Confident and Stonewall Diversity Champions Programme, we welcome applications from people identifying with these characteristics. The University has a number of staff networks which provide peer support and safe spaces for staff who hold these and other identities.
Type / Role: